Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jon E Arnason, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Koshy AG, Kim HT, Liegel J, Arnason JE, Ho VT, Antin JH, Joyce R, Cutler CS, Gooptu M, Nikiforow S, Logan EK, Elavalakanar P, Narcis M, Stroopinsky D, Avigan ZM, Boussi L, Stephenson SL, El Banna H, Bindal P, Cheloni G, Avigan DE, Soiffer RJ, Rosenblatt J. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease. Blood. 2023 Mar 02. PMID: 36862975.
    Citations:    Fields:    
  2. Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, Izutsu K, Morschhauser F, Lunning MA, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood. 2022 Dec 21. PMID: 36542826.
    Citations: 1     Fields:    
  3. Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason J, Glass B, Mutsaers P, Lunning M, Braverman J, Liu FF, Crotta A, Montheard S, Previtali A, Guo S, Shi L, Solomon SR. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022 12 13; 6(23):5969-5979. PMID: 36149968; PMCID: PMC9713278.
    Citations:    Fields:    Translation:Humans
  4. Sermer D, Elavalakanar P, Abramson JS, Palomba ML, Salles G, Arnason J. Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation. Blood Rev. 2023 01; 57:101002. PMID: 35989138.
    Citations:    Fields:    Translation:HumansCells
  5. Weinstock M, Elavalakanar P, Bright S, Ambati SR, Brouwer-Visser J, Pourpe S, Fiaschi N, Jankovic V, Thurston G, Deering RP, Chaudhry A, Joyce R, Arnason J. Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy. Br J Haematol. 2022 11; 199(3):366-370. PMID: 35892294; PMCID: PMC9796753.
    Citations:    Fields:    
  6. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 06 18; 399(10343):2294-2308. PMID: 35717989.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  7. Jalbert JJ, Wu N, Chen CI, Ambati S, Ge W, Arnason JE. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma. Adv Ther. 2022 06; 39(6):2630-2640. PMID: 35397110; PMCID: PMC9123047.
    Citations:    Fields:    Translation:Humans
  8. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May; 9(5):e327-e339. PMID: 35366963.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  9. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806. PMID: 34699592.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  10. Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2022 03; 36(3):723-732. PMID: 34743191; PMCID: PMC8891037.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  11. Ahrendsen JT, Sehgal K, Sarangi S, Uhlmann EJ, Varma H, Arnason J, Avigan D. Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma. J Hematol. 2021 Oct; 10(5):212-216. PMID: 34804310.
    Citations:    
  12. Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402. PMID: 34534514.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  13. Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2022 01; 63(1):54-63. PMID: 34510995.
    Citations:    Fields:    Translation:Humans
  14. Trottier CA, Yen CF, Malvar G, Arnason J, Avigan DE, Alonso CD. Case Report: Refractory Cryptosporidiosis after CAR T-Cell Therapy for Lymphoma. Am J Trop Med Hyg. 2021 07 08; 105(3):651-653. PMID: 34237021; PMCID: PMC8592362.
    Citations:    Fields:    Translation:Humans
  15. Miller PG, Sperling AS, Gibson CJ, Viswanathan K, Castellano C, McConkey M, Ceremsak J, Taylor MS, Birndt S, Perner F, Arnason J, Agrawal M, Schram AM, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL. Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood. 2020 12 24; 136(26):3051-3055. PMID: 32961550; PMCID: PMC7770567.
    Citations: 6     Fields:    Translation:HumansAnimals
  16. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 09 19; 396(10254):839-852. PMID: 32888407.
    Citations: 269     Fields:    Translation:HumansCellsCTClinical Trials
  17. Davids MS, Fisher DC, Tyekucheva S, McDonough M, Hanna J, Lee B, Francoeur K, Montegaard J, Odejide O, Armand P, Arnason J, Brown JR. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 2021 04; 35(4):1064-1072. PMID: 32820271.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  18. Miller PG, Niroula A, Ceremsak JJ, Gibson CJ, Taylor MS, Birndt S, Perner F, Arnason J, Sperling AS, Agrawal M, Schram AM, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL. Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2020 03 10; 4(5):925-929. PMID: 32150605.
    Citations: 3     Fields:    Translation:HumansCells
  19. Raz MA, Arnason J, Bairey O, Shvidel L, Aviv A, Ben Baruch S, Perry C, Sarid N, Kirgner I, Dvid V, Herishanu Y, Avivi I. The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. Br J Haematol. 2020 04; 189(2):e31-e33. PMID: 32150642.
    Citations: 1     Fields:    Translation:Humans
  20. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. PMID: 31723987.
    Citations:    
  21. Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428. PMID: 31208944; PMCID: PMC7036668.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  22. Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 08 15; 134(7):606-613. PMID: 31186274.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  23. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. PMID: 30967392.
    Citations: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  24. Feld J, Arnason J, O Apos Brien K, Nahas M. Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. Acta Haematol. 2019; 141(4):222-224. PMID: 30947164.
    Citations: 2     Fields:    Translation:Humans
  25. Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019 Jan; 6(1):e38-e47. PMID: 30558987; PMCID: PMC7132223.
    Citations: 38     Fields:    Translation:HumansCTClinical Trials
  26. Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR. Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leuk Lymphoma. 2019 05; 60(5):1312-1315. PMID: 30322319.
    Citations: 1     Fields:    Translation:HumansCells
  27. Nahas MR, Soiffer RJ, Kim HT, Alyea EP, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845. PMID: 29549175.
    Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
  28. Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018 Apr; 5(4):e170-e180. PMID: 29550382; PMCID: PMC7029813.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  29. Leaf RK, Stroopinsky D, Pyzer AR, Kruisbeek AM, van Wetering S, Washington A, Ephraim A, Cole L, Morin A, Jain S, Nahas MR, Apel A, Arnason J, Hamdan A, Rosenblatt J, Avigan D. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma. J Immunother. 2017 Nov/Dec; 40(9):315-322. PMID: 28961609.
    Citations: 7     Fields:    Translation:HumansCells
  30. Arnason JE, Brown JR. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Curr Oncol Rep. 2017 Sep; 19(9):61. PMID: 28755313.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  31. Jain S, Washington A, Leaf RK, Bhargava P, Clark RA, Kupper TS, Stroopinsky D, Pyzer A, Cole L, Nahas M, Apel A, Rosenblatt J, Arnason J, Kufe D, Avigan D. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2017 10; 16(10):2304-2314. PMID: 28729399; PMCID: PMC5628140.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  32. Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017 12; 31(12):2780-2790. PMID: 28555079.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  33. Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801. PMID: 28126925; PMCID: PMC5813734.
    Citations: 61     Fields:    Translation:HumansAnimalsCells
  34. Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938. PMID: 28107546; PMCID: PMC5800979.
    Citations: 12     Fields:    Translation:HumansCells
  35. Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171. PMID: 27928025; PMCID: PMC5800949.
    Citations: 72     Fields:    Translation:HumansCellsPHPublic Health
  36. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. PMID: 27247136; PMCID: PMC4946200.
    Citations: 120     Fields:    Translation:HumansCTClinical Trials
  37. Yigit B, Halibozek PJ, Chen SS, O'Keeffe MS, Arnason J, Avigan D, Gattei V, Bhan A, Cen O, Longnecker R, Chiorazzi N, Wang N, Engel P, Terhorst C. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget. 2016 May 03; 7(18):26346-60. PMID: 27029059; PMCID: PMC5041984.
    Citations: 7     Fields:    Translation:HumansAnimals
  38. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016 Feb; 172(3):412-9. PMID: 26537747.
    Citations: 35     Fields:    Translation:Humans
  39. Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS One. 2015; 10(6):e0130518. PMID: 26110267.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  40. Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Jul 16; 126(3):354-62. PMID: 26048911; PMCID: PMC4504948.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  41. Arnason JE, Luptakova K, Rosenblatt J, Tzachanis D, Avigan D, Zwicker JI, Levine J, Kim M, Parker JA, Grant B, Joyce RM. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. Acta Haematol. 2015; 133(4):347-53. PMID: 25677780.
    Citations: 1     Fields:    Translation:Humans
  42. Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 2015 Feb; 75(2):143-55. PMID: 25619739.
    Citations: 2     Fields:    Translation:HumansCells
  43. Arnason JE, Brown JR. B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. Immunotargets Ther. 2014; 3:29-38. PMID: 27471698; PMCID: PMC4918232.
    Citations: 3     
  44. Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79. PMID: 23867470.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  45. Warner JL, Arnason JE. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol. 2012 Dec; 3(6):375-89. PMID: 23606939.
    Citations: 6     
  46. Arnason J, Avigan D. Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma. Immunotherapy. 2012 Oct; 4(10):1043-51. PMID: 23148756.
    Citations: 5     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  47. Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49. PMID: 22733396.
    Citations: 78     Fields:    Translation:HumansCells
  48. Arnason JE, Campigotto F, Neuberg D, Bussel JB. Abnormalities in IgA and IgM are associated with treatment-resistant ITP. Blood. 2012 May 24; 119(21):5016-20. PMID: 22490683.
    Citations: 4     Fields:    Translation:HumansCells
  49. Arnason JE, Brown JR. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected]. Hematology Am Soc Hematol Educ Program. 2011; 2011:119-20. PMID: 22160022.
    Citations: 2     Fields:    Translation:HumansCells
  50. Gergis U, Arnason J, Yantiss R, Shore T, Wissa U, Feldman E, Woodworth T. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Oncol. 2010 Oct 20; 28(30):e602-4. PMID: 20713858.
    Citations: 13     Fields:    Translation:Humans
  51. Levy B, Arnason JE, Bussel JB. The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. Curr Opin Oncol. 2008 Nov; 20(6):690-6. PMID: 18841052.
    Citations: 9     Fields:    Translation:HumansCells
  52. Arnason JA, Jónsson T, Brekkan A, Sigurjónsson K, Valdimarsson H. Relation between bone erosions and rheumatoid factor isotypes. Ann Rheum Dis. 1987 May; 46(5):380-4. PMID: 3592799; PMCID: PMC1002145.
    Citations: 15     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Arnason's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (239)
Explore
_
Co-Authors (70)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.